NCI-2020-02981

Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma

To help the body’s immune response against tumors, doctors have created a medicine called Voyager V1 or VV1. This is a synthetic virus that intensifies the anti-tumor immune responses and affects only the tumor cells and not the healthy ones. This research study will study the benefits and effects of the treatment with Voyager V1 when fighting tumors, and see if it is safe when combined with the drug, Cemiplimab, in patients with advanced and progressing types of the cancers that progress on treatment with Checkpoint Inhibitors (CPIs). Drugs called “checkpoint inhibitors” work by releasing a natural brake on your immune system so that immune cells can recognize and attack tumors. Cemiplimab is a monoclonal antibody which is an immune therapy. The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04291105

NCI-2020-02981

Clinical Trial Site: Sinai

To see all available clinical trials click here.